190 related articles for article (PubMed ID: 34897227)
1. Brief Report: Bictegravir/Emtricitabine/Tenofovir Alafenamide Efficacy in Participants With Preexisting Primary Integrase Inhibitor Resistance Through 48 Weeks of Phase 3 Clinical Trials.
D'Antoni ML; Andreatta K; Acosta R; Martin H; Chang S; Martin R; White KL
J Acquir Immune Defic Syndr; 2022 Apr; 89(4):433-440. PubMed ID: 34897227
[TBL] [Abstract][Full Text] [Related]
2. Three-year study of pre-existing drug resistance substitutions and efficacy of bictegravir/emtricitabine/tenofovir alafenamide in HIV-1 treatment-naive participants.
Acosta RK; Chen GQ; Chang S; Martin R; Wang X; Huang H; Brainard D; Collins SE; Martin H; White KL
J Antimicrob Chemother; 2021 Jul; 76(8):2153-2157. PubMed ID: 33880558
[TBL] [Abstract][Full Text] [Related]
3. Brief Report: Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Females Living With HIV: An Integrated Analysis of 5 Trials.
Orkin C; Ajana F; Kityo C; Koenig E; Natukunda E; Gandhi-Patel B; Wang H; Liu Y; Wei X; White K; Makadzange T; Pikora C; McNicholl I; Collins SE; Brainard D; Chuck SK
J Acquir Immune Defic Syndr; 2021 Dec; 88(4):393-398. PubMed ID: 34506342
[TBL] [Abstract][Full Text] [Related]
4. High efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide in people with suppressed HIV and preexisting M184V/I.
Sax PE; Andreatta K; Molina JM; Daar ES; Hagins D; Acosta R; D'Antoni ML; Chang S; Martin R; Liu H; Blair C; McNicholl I; Gallant J; Collins SE; Martin H; White KL
AIDS; 2022 Sep; 36(11):1511-1520. PubMed ID: 35466963
[TBL] [Abstract][Full Text] [Related]
5. Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus.
Sax PE; Rockstroh JK; Luetkemeyer AF; Yazdanpanah Y; Ward D; Trottier B; Rieger A; Liu H; Acosta R; Collins SE; Brainard DM; Martin H;
Clin Infect Dis; 2021 Jul; 73(2):e485-e493. PubMed ID: 32668455
[TBL] [Abstract][Full Text] [Related]
6. Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-existing NRTI Resistance.
Acosta RK; Willkom M; Andreatta K; Liu H; Martin R; Parvangada A; Martin H; Collins S; White KL
J Acquir Immune Defic Syndr; 2020 Nov; 85(3):363-371. PubMed ID: 32701823
[TBL] [Abstract][Full Text] [Related]
7. Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study.
Hagins D; Kumar P; Saag M; Wurapa AK; Brar I; Berger D; Osiyemi O; Hileman CO; Ramgopal MN; McDonald C; Blair C; Andreatta K; Collins SE; Brainard DM; Martin H;
J Acquir Immune Defic Syndr; 2021 Sep; 88(1):86-95. PubMed ID: 34397746
[TBL] [Abstract][Full Text] [Related]
8. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
Gallant J; Lazzarin A; Mills A; Orkin C; Podzamczer D; Tebas P; Girard PM; Brar I; Daar ES; Wohl D; Rockstroh J; Wei X; Custodio J; White K; Martin H; Cheng A; Quirk E
Lancet; 2017 Nov; 390(10107):2063-2072. PubMed ID: 28867497
[TBL] [Abstract][Full Text] [Related]
9. Integrase strand transfer inhibitor resistance mediated by R263K plus E157Q in a patient with HIV infection treated with bictegravir/tenofovir alafenamide/emtricitabine: case report and review of the literature.
Buzon-Martin L; Navarro-San Francisco C; Fernandez-Regueras M; Sanchez-Gomez L
J Antimicrob Chemother; 2024 May; 79(5):1153-1156. PubMed ID: 38558010
[TBL] [Abstract][Full Text] [Related]
10. Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial.
Sax PE; DeJesus E; Crofoot G; Ward D; Benson P; Dretler R; Mills A; Brinson C; Peloquin J; Wei X; White K; Cheng A; Martin H; Quirk E
Lancet HIV; 2017 Apr; 4(4):e154-e160. PubMed ID: 28219610
[TBL] [Abstract][Full Text] [Related]
11. Bictegravir/emtricitabine/tenofovir alafenamide ensures high rates of virological suppression maintenance despite previous resistance in PLWH who optimize treatment in clinical practice.
Armenia D; Forbici F; Bertoli A; Berno G; Malagnino V; Gagliardini R; Borghi V; Gennari W; Cicalini S; Buonomini A; Teti E; Lanini S; Latini A; Sarmati L; Mussini C; Andreoni M; Antinori A; Perno CF; Ceccherini-Silberstein F; Santoro MM
J Glob Antimicrob Resist; 2022 Sep; 30():326-334. PubMed ID: 35793776
[TBL] [Abstract][Full Text] [Related]
12. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
Molina JM; Ward D; Brar I; Mills A; Stellbrink HJ; López-Cortés L; Ruane P; Podzamczer D; Brinson C; Custodio J; Liu H; Andreatta K; Martin H; Cheng A; Quirk E
Lancet HIV; 2018 Jul; 5(7):e357-e365. PubMed ID: 29925489
[TBL] [Abstract][Full Text] [Related]
13. Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide in adolescents and children with HIV: week 48 results of a single-arm, open-label, multicentre, phase 2/3 trial.
Gaur AH; Cotton MF; Rodriguez CA; McGrath EJ; Helström E; Liberty A; Natukunda E; Kosalaraksa P; Chokephaibulkit K; Maxwell H; Wong P; Porter D; Majeed S; Yue MS; Graham H; Martin H; Brainard DM; Pikora C
Lancet Child Adolesc Health; 2021 Sep; 5(9):642-651. PubMed ID: 34302760
[TBL] [Abstract][Full Text] [Related]
14. Switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir-based therapy.
Orkin C; Antinori A; Rockstroh JK; Moreno-Guillén S; Martorell CT; Molina JM; Lazzarin A; Maggiolo F; Yazdanpanah Y; Andreatta K; Huang H; Hindman JT; Martin H; Pozniak A
AIDS; 2024 Jun; 38(7):983-991. PubMed ID: 38349226
[TBL] [Abstract][Full Text] [Related]
15. Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.
Wohl DA; Yazdanpanah Y; Baumgarten A; Clarke A; Thompson MA; Brinson C; Hagins D; Ramgopal MN; Antinori A; Wei X; Acosta R; Collins SE; Brainard D; Martin H
Lancet HIV; 2019 Jun; 6(6):e355-e363. PubMed ID: 31068270
[TBL] [Abstract][Full Text] [Related]
16. Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial.
Mills AM; Rizzardini G; Ramgopal MN; Osiyemi OO; Bogner JR; Hagins DP; Paredes R; Reynes J; Rockstroh JK; Carr A; Su FH; Klopfer SO; Eves K; Plank RM; Correll T; Fox MC
Lancet HIV; 2024 Jun; 11(6):e357-e368. PubMed ID: 38734016
[TBL] [Abstract][Full Text] [Related]
17. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial.
Sax PE; Pozniak A; Montes ML; Koenig E; DeJesus E; Stellbrink HJ; Antinori A; Workowski K; Slim J; Reynes J; Garner W; Custodio J; White K; SenGupta D; Cheng A; Quirk E
Lancet; 2017 Nov; 390(10107):2073-2082. PubMed ID: 28867499
[TBL] [Abstract][Full Text] [Related]
18. Increased viral load in a hospitalized patient on treatment with crushed bictegravir/emtricitabine/tenofovir alafenamide: A case report and review of the literature.
Rowe SM; Clary JC; Drummond M; Derrick C; Sanasi K; Bookstaver PB
Am J Health Syst Pharm; 2022 Aug; 79(16):1330-1336. PubMed ID: 35511892
[TBL] [Abstract][Full Text] [Related]
19. A phase IV randomised, open-label pilot study to evaluate switching from protease-inhibitor based regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide single tablet regimen in Integrase inhibitor-naïve, virologically suppressed HIV-1 infected adults harbouring drug resistance mutations (PIBIK study): study protocol for a randomised trial.
Iwuji CC; Churchill D; Bremner S; Perry N; To Y; Lambert D; Bruce C; Waters L; Orkin C; Geretti AM
BMC Infect Dis; 2020 Jul; 20(1):524. PubMed ID: 32689975
[TBL] [Abstract][Full Text] [Related]
20. Patient-Reported Symptoms Over 48 Weeks Among Participants in Randomized, Double-Blind, Phase III Non-inferiority Trials of Adults with HIV on Co-formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Co-formulated Abacavir, Dolutegravir, and Lamivudine.
Wohl D; Clarke A; Maggiolo F; Garner W; Laouri M; Martin H; Quirk E
Patient; 2018 Oct; 11(5):561-573. PubMed ID: 29956087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
